Japanese company places order for Nutranomics’ natural testosterone booster formula

Nutranomics, Inc. (OTCBB: NNRX) (OTCQB: NNRX) ("Nutranomics" or the "Company") is pleased to report that it has received a purchase order for 500,000 capsules of a natural testosterone booster formula recently developed by Nutranomics. The initial purchase order is the result of a successful custom product development request made several months ago by a confidential Japanese nutritional supplement company.

"In just three months, our team successfully utilized its extensive product development skills to custom create this natural testosterone booster formula and secure an initial purchase order from a first-time Japanese client," stated Nutranomics CEO, Dr. Tracy K. Gibbs. "Although the initial purchase order for $24,000 is not substantially large, once again, this shows that our current Asian markets expansion strategy has been successful at generating new business from entirely new client channels. We anticipate developing other custom formulated products for this client in the future and potentially securing recurring purchase orders."

Dr. Gibbs concluded, "I look forward to exploring other possible distribution and private label opportunities for the Nutranomics testosterone booster formula in other markets."

Source:

Nutranomics, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers develop stable compound for targeted alpha therapy in prostate cancer